Nutra Pharma Announces Direct Response Television Campaign for Pet Pain-Away™
Nutra Pharma Corp.
Nutra Pharma is announcing the next phase of marketing their Over-the-Counter (OTC) pain reliever for dogs and cats, Pet Pain-Away™ through their direct response partner, DEG Productions.
June 6, 2018 -- Coral Springs, Florida -- Nutra Pharma Corporation (OTC: NPHC), a biotechnology company marketing Nyloxin® and Pet Pain-Away™ in the over-the-counter (OTC) pain management market, announced today that DEG Productions has initiated a re-launch of its national direct response television campaign to market the Pet Pain Away brand of homeopathic pain relief products for pets.
“We could not be happier with the progress that DEG Productions is making in their marketing of Pet Pain-Away,” commented Rik J Deitsch, CEO of Nutra Pharma Corporation. "They have been diligently testing the marketing message for the product and are ready for the next phase of their campaign," he continued. "Their advertising features companion animals that are actual product users. We know that there is no such thing as a placebo effect in dogs and cats. Seeing the positive results of using Pet Pain-Away in these family pets is truly inspiring," he concluded.
Pet Pain-Away is a homeopathic, non-narcotic, non-addictive, over-the-counter pain reliever. The product is primarily aimed at treating moderate to severe chronic pain in companion animals. It is specifically indicated to treat pain from hip dysplasia, arthritis pain, joint pain, and general chronic pain in dogs and cats. Specialized proteins in Pet Pain-Away block the action of acetylcholine, a major stimulating neurotransmitter in the nervous system and activator of the inflammatory pathways. As a result, the pain and inflammation pathways are temporarily shut off.
“The two-minute short-form commercial features compelling testimonials of actual pet owners describing their personal stories about the dramatic results that Pet Pain Away has delivered for their cherished pets,” commented Dan Sladkus, Co-President of DEG Productions. “The commercial also educates potential buyers about the product’s revolutionary pain blocking effects and takes advantage of the proven results of the product by offering new customers a ‘risk-free trial’ in which they can order the product at no cost and receive it by paying a small shipping and handling fee of only $5.95,” he continued. “Based on prior results from months of previous testing of the commercial, DEG is confident that customer retention in the auto-ship program will remain strong. Our data has shown that the typical customer is likely to stay with the program for three to six months on average,” he concluded.
Nutra Pharma has stated that the goal of the television campaign is to potentially convert thousands of single purchase customers into a monthly continuity or “auto-ship” program. The projected geometric growth in sales is key to rolling out the television campaign onto larger and larger platforms.
According to The American Pet Products Association (APPA) there are 89.7 million dogs and 94.2 million cats in the US. These companion animals are as susceptible as humans to ailments that require pain-relieving solutions. The total market for companion animals in the US reached an estimated $69.5 billion in 2017. Of these expenditures, over $15 billion was spent on medication for the animals. Additionally, a 2009 survey conducted by Virbac Pharmaceuticals puts the annual US market for companion animal pain relievers at more than $250 million.
For additional information on DEG Productions, visit: http://www.degproductions.tv
About Nutra Pharma Corp.
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. Additionally, the Company markets drug products for sale for the treatment of pain under the brand Nyloxin® and Pet Pain-Away™.
For additional information about Nutra Pharma, visit:
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The commercial campaign for Pet Pain-Away should not be construed as an indication in any way whatsoever of the future value of the Company’s common stock or its financial value. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.